| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
| Targets |
The primary reactive target of DSPE-PEG-NHS is primary amine groups (-NH₂) on proteins, peptides, antibodies, and other biomolecules. The NHS ester group is the key reactive moiety that facilitates this conjugation. The DSPE component anchors the molecule into lipid bilayers, providing stability. The PEG component improves hydrophilicity, reduces opsonization, and enhances the solubility and biocompatibility of the conjugate. The molecule is not a drug that targets a biological receptor but a functionalized lipid used for drug delivery and bioconjugation.
|
|---|---|
| ln Vitro |
In vitro, DSPE-PEG-NHS is used to functionalize liposomes and nanoparticles for targeted drug delivery. The NHS ester reacts with primary amines on targeting ligands, such as antibodies or peptides, under mild conditions (pH 8-10) to form stable amide bonds. The PEG spacer provides flexibility and reduces non-specific interactions. The DSPE component anchors the conjugate into lipid bilayers, creating stable, functionalized nanocarriers. The compound is used to prepare targeted liposomes for in vitro cell uptake and efficacy studies.
|
| ln Vivo |
In vivo, DSPE-PEG-NHS is used to create targeted lipid nanoparticles (LNPs) and liposomes for drug delivery. The NHS ester allows the attachment of targeting moieties that direct the nanoparticles to specific tissues or cells. The PEG component prolongs circulation time by reducing opsonization and clearance by the reticuloendothelial system. The DSPE component provides stability to the lipid bilayer. These functionalized nanoparticles are used for the delivery of chemotherapeutics, nucleic acids, and imaging agents in various disease models.
|
| Enzyme Assay |
In vitro conjugation protocols involve incubating DSPE-PEG-NHS with amine-containing molecules in a suitable buffer at pH 8-10. The reaction is typically carried out at room temperature for several hours. The NHS ester reacts with primary amines to form stable amide bonds. The conjugation efficiency can be monitored by techniques such as gel electrophoresis or mass spectrometry. The resulting DSPE-PEG-ligand conjugate can then be incorporated into liposomes or nanoparticles by thin-film hydration or other standard methods. The compound is for research use only.
|
| Animal Protocol |
In vivo protocols involve the preparation of DSPE-PEG-NHS functionalized liposomes or nanoparticles containing a therapeutic or imaging agent. The nanoparticles are typically administered intravenously to animal models. The targeting ligands attached via the NHS ester direct the nanoparticles to specific tissues, enhancing drug accumulation and efficacy. The PEG component prolongs circulation time. The animals are then monitored for therapeutic response, biodistribution, and toxicity. The protocols are established for various disease models, including cancer and inflammatory diseases.
|
| ADME/Pharmacokinetics |
DSPE-PEG-NHS is an amphiphilic molecule with a molecular weight of approximately 927.08 for the PEG-free form, but the actual molecular weight depends on the PEG chain length. The molecule is soluble in DMSO and can be incorporated into lipid bilayers. The NHS ester is reactive towards primary amines at pH 8-10. The PEG component improves water solubility and biocompatibility. The compound should be stored as a powder at -20°C for up to 3 years or at 4°C for up to 2 years. In solvent, it is stable at -80°C for 6 months and at -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
DSPE-PEG-NHS is considered relatively non-toxic as it is a biocompatible lipid-PEG conjugate. However, the NHS ester can react with primary amines on proteins, potentially causing irritation or allergic reactions. The compound is for research use only and not for human therapeutic use. It should be handled with appropriate safety precautions, including the use of personal protective equipment. The compound should be stored in a sealed container in a cool, dry place away from moisture and incompatible materials.
|
| Additional Infomation |
DSPE-PEG-NHS is also known as 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol-N-hydroxysuccinimide. It is an amphiphilic molecule that combines a lipid anchor (DSPE), a hydrophilic spacer (PEG), and an activated ester (NHS). It is used for the conjugation of proteins, peptides, and antibodies to liposomes and nanoparticles. The NHS ester reacts specifically with primary amines at pH 8-10. It is supplied as a solid powder and should be stored at -20°C. It is for research use only.
|
| Molecular Formula |
C47H74O18
|
|---|---|
| Molecular Weight |
927.08
|
| CAS # |
1445723-73-8
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0787 mL | 5.3933 mL | 10.7866 mL | |
| 5 mM | 0.2157 mL | 1.0787 mL | 2.1573 mL | |
| 10 mM | 0.1079 mL | 0.5393 mL | 1.0787 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
